Can multiple myeloma treatment move out of the hospital? new study tests Home-Based dosing
NCT ID NCT06251076
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether teclistamab, a drug for relapsed or refractory multiple myeloma, can be given safely outside the hospital. It involves 15 patients who have tried at least 3 prior treatments. The goal is to develop a clear process for outpatient care and measure how this affects caregivers' quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact